Daily FNArena News

Life sciences sector analyst Stuart Roberts reports Celldex Therapeutics (Nasdaq: CLDX) is in Phase III with a cancer vaccine which can double median overall survival for glioblastoma patients.

The Chartist reports a corrective phase is underway for Wesfarmers but the technicals suggest longer term investors may like to set up for some subsequent blue sky.

A wrap of the day’s activity on the Australian stock market.

At its AGM WorleyParsons surprised some brokers, guiding to growth in FY14 while announcing the first half earnings would be weaker than expected.

FNArena’s weekly update on short positions in the Australian share market.

China’s seasons matter more these days to commodities, uranium remains under pressure and Macquarie thinks nickel prices have turned a corner.

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. The overvalued bank question has become a bit hackneyed, but it doesn’t stop brokers still offering opposing views on the matter.

Jonathan Barratt of Barratt’s Bulletin notes US inflation is waning again. The new Fed chair may yet provide more gold-positive stimulus.

A wrap of the day’s activity on the Australian stock market.

Metals prices could be in a trading range, according to Citi. JP Morgan shuffles key base metal picks while Macquarie surveys investors at the LME summit.